MineGene (06667) announced results for the year ended December 31, 2023. The group recorded revenue of 1...
According to the Zhitong Finance App, Meiyin Gene (06667) announced the results for the year ended December 31, 2023. The group recorded revenue of 151 million yuan, an increase of 3.8% over the previous year, and net profit of RMB 30.38 million, turning a year-on-year loss into a profit. Basic earnings per share were $0.14.
For the year ended December 31, 2023, revenue growth was 3.8%; without taking into account the impact of COVID-19 testing services, revenue growth was 16.8%. Among them, the revenue generated by consumer-grade genetic testing services and cancer screening services for the year ended 31 December 2023 was RMB 108 million and RMB 43 million, respectively. Revenue increased year-on-year, mainly due to the company implementing a more active market strategy, speeding up sales channel expansion, enriching the product matrix, and continuously optimizing the product structure of genetic testing services during the reporting period, resulting in a steady year-on-year increase in revenue.